#United States #New York #Securities Fraud #Rosen Law Firm #Applied Therapeutics

A Crucial Opportunity for Investors of Applied Therapeutics

Investors who purchased securities of Applied Therapeutics, Inc. (NASDAQ: APLT) between January 3, 2024, and December 2, 2024, are reminded of a significant opportunity to lead a class action lawsuit concerning allegations of securities fraud. The Rosen Law Firm, a recognized global leader in investor rights, is encouraging affected purchasers to consider their legal options before the lead plaintiff application deadline of February 18, 2025.

Understanding the Context

During the specified class period, numerous allegations concerning the handling of clinical trial protocols by Applied Therapeutics surfaced, raising concerns about the integrity of the company's data and practices. The lawsuit claims that the company failed to adhere to proper clinical standards, thereby misleading investors about the viability and approval processes of its clinical trials. This misleading information potentially led to substantial financial losses when the truth about the adherence to regulatory protocols came to light.

What Needs to Be Done

If you are a shareholder within the specified dates, you might be eligible to participate in the class action without incurring any personal legal fees. Interested individuals should either submit their details online via Rosen Law Firm's website or contact attorney Phillip Kim at their toll-free number, 866-767-3653.

The process of becoming a lead plaintiff also involves a court motion due before the February deadline. This role entails representing the interests of fellow investors while directing litigation efforts.

Why Choose Rosen Law Firm?

Rosen Law Firm emphasizes the importance of selecting a law firm with a proven success record in handling securities class actions. Notably, the firm achieved the largest ever settlement against a Chinese company and has been consistently ranked among the top firms handling securities litigation since 2013. Their ability to recover large sums for investors is underscored by their impressive track record, including over $438 million for investors in just one year, 2019.

Details of the Allegations

The lawsuit's core allegations state that during the class period, numerous statements made by Applied Therapeutics were either false or misleading. According to the suit, the company failed to follow necessary trial protocols and good clinical practices, thus jeopardizing the approval prospects with the FDA for its new drug applications. When these practices were disclosed, many investors reportedly faced significant losses as a consequence of the revelation.

Steps to Consider

As an investor, you might have several pathways to go about joining this legal endeavor. Firstly, you can opt to participate actively, serving as a lead plaintiff, or you can remain an absent class member, choosing not to take immediate action. Importantly, your potential to participate in any future recoveries is not dependent on whether you become a lead plaintiff or not.

Investors are encouraged to keep informed through the firm's updates on their social media platforms including LinkedIn, Twitter, and Facebook, while also considering their legal options carefully.
Additionally, while individual representation prior to class certification is an option, acting promptly is crucial to not miss out on your potential claims.

Conclusion

The looming February deadline necessitates urgent action from those involved. With the stakes high and the legal pathways intricate, affected investors are strongly advised to engage with competent legal counsel who can navigate the complexities of securities litigation. Rosen Law Firm's established expertise makes it a leading candidate for investors seeking to assert their rights following what is alleged to be misconduct by Applied Therapeutics.